• Mashup Score: 7

    Bonazzi et al. describe the discovery of clinical candidate NVP-DKY709, a selective degrader of the IKZF2 transcription factor that was identified on the basis of recruitment of IKZF2 to CRBN. NVP-DKY709 treatment reduces suppression by human regulatory T cells in vitro, reduces tumor growth in mice, and degrades IKZF2 in monkeys and humans.

    Tweet Tweets with this article
    • Our first in class therapeutic targeting the Helios transcription factor, here via TPD via molecular glues. New target in the IO landscape, oral therapy. All fingers crossed for anti cancer activity of this program in patients with advanced cancer. https://t.co/lcS6XBexlJ

  • Mashup Score: 0

    Bioluminescent probes are routinely used to track biological processes in vitro and in vivo. Multiplexed imaging remains challenging, though, owing to a lack of well-resolved probes and lengthy acquisition times. Brennan et al. report a straightforward platform for rapid, quantitative analyses of bioluminescent mixtures.

    Tweet Tweets with this article
    • Read now in @CellChemBiol "Multiplexed bioluminescence imaging with a generalized substrate unmixing platform" by @jenn_prescher @UCIChemistry & others #bps2023 https://t.co/brid7mejcE